Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Antibodies
Filter     Order     Display # 
Date Item Title
03 Aug 2007 Genmab regains rights to HuMax-TAC
03 Aug 2007 Macrogenics Begins Global Phase 2/3 Protege Study In Recent-onset Type 1 Diabetes Mellitus
02 Aug 2007 ImmunoGen, Inc. Initiates Phase II Clinical Trial of HuC242-DM4
02 Aug 2007 Phase 2a Multi-dose Study Initiated By Medimmune In Patients With Asthma To Further Expand Anti-interleukin-9 Program
01 Aug 2007 ImmunoGen, Inc. Earns Milestone with Start of Trastuzumab-DM1 Phase II Testing
01 Aug 2007 Preliminary Data Add New Mechanistic Insights to Activity of Anthrax Anti-Toxin, Valortim(TM)
01 Aug 2007 YM BioSciences initiates patient enrolment in phase II colorectal cancer trial with EGFR antibody
01 Aug 2007 Joint FDA Advisory Committee Recommends Approval of TYSABRI(R) for the Treatment of Moderate to Severe Crohn's Disease
31 Jul 2007 BioWa Introduces its Second Technology to Dramatically Enhance Antibody Effector Function and the Launch of AccretaMab(TM) Platform
28 Jul 2007 US Food & Drug Administration approves Privigen(TM)
26 Jul 2007 Actemra monotherapy demonstrates significant clinical benefit in patients with rheumatoid arthritis
26 Jul 2007 Progenics Presents Additional Positive Clinical Results for HIV-Entry Inhibitor PRO 140 at International AIDS Meeting
24 Jul 2007 Amorfix acheives first milestone in herapeutic ALS partnership with Biogen Idec
24 Jul 2007 MedImmune Announces Interim Phase 1 Study Results for Potential Asthma Therapy
21 Jul 2007 Avastin receives positive opinion in Europe for first-line treatment of patients with advanced lung cancer
20 Jul 2007 Glenmark purchases rights to two therapeutic antibodies from Chromos
20 Jul 2007 Medarex Announces Advancement of Antibody Development by Partner
19 Jul 2007 Medarex Announces Initiation by Licensing Partner of Phase III Clinical Trial for Muckle Wells Syndrome
18 Jul 2007 Secondary endpoints of phase II/III study confirm clear benefits from treatment with removab(R) for patients with malignant ascites
17 Jul 2007 XOMA Initiates Phase I U.S. Trial in Type 2 Diabetes for XOMA 052, Monoclonal Antibody With Therapeutic Potential in Multiple Inflammatory Diseases
14 Jul 2007 CSL Behring Completes Enrollment for Phase III Registration Trial of Next Generation of Subcutaneous Immunoglobulin
13 Jul 2007 Amgen and Daiichi Sankyo announce agreement for denosumab in Japan
13 Jul 2007 Data Available From ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Lung Cancer
13 Jul 2007 Phase II Study of IMC-A12 for Advanced Colorectal Cancer Has Commenced Patient Enrollment
12 Jul 2007 Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Lung Cancer Patients
12 Jul 2007 TRACON Pharmaceuticals and Micromet Announce the Initiation of Phase 1 Clinical Trial with TRC093 (D93), a Humanized Antibody for Cancer Treatment
11 Jul 2007 Actemra: latest phase III study shows significant improvement in symptoms of patients with rheumatoid arthritis
11 Jul 2007 Peregrine Pharmaceuticals Initiates Bavituximab Clinical Trial in HCV Patients Co-Infected With HIV
10 Jul 2007 MacroGenics IND for West Nile Virus Monoclonal Antibody is Active
03 Jul 2007 Ablynx announces interim results of first nanobody (R) phase i study of ALX-0081 (anti-vWF)
03 Jul 2007 Lexicon Develops Antibodies that Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
02 Jul 2007 Genmab announces final humax-CD4 Phase II CTCL data
30 Jun 2007 Genmab regains rights to HuMax-CD4
30 Jun 2007 WILEX to follow FDA advice and apply for a special protocol assessment (SPA) for CA9-SCAN
23 Jun 2007 Alexion's Soliris(TM) granted marketing approval in europe for treatment of all patients with PNH
22 Jun 2007 Viragen Streamlines Research Focus and Halts Further Development of OVA(TM) System
20 Jun 2007 Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
19 Jun 2007 Vegenics Licenses From CoGenesys Antibodies Against VEGF-C for Applications Including Oncology
16 Jun 2007 Actemra: Roche's novel rheumatoid arthritis drug shows substantial benefits for patients in OPTION study
16 Jun 2007 GlaxoSmithKlline and Genmab present positive Phase II results with ofatumumab in patients with rheumatoid arthritis (RA)
16 Jun 2007 GlaxoSmithKlline and Genmab present positive Phase II results with ofatumumab in patients with rheumatoid arthritis (RA)
16 Jun 2007 Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia(R) (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
15 Jun 2007 Anti-TNF golimumab continues to show promise in Phase II rheumatoid arthritis study
15 Jun 2007 CIMZIA(TM) Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
15 Jun 2007 Human Genome Sciences reports that a Phase 2 study of LymphoStat-B(R) showed significant reductions in disease activity in patients with active systemic lupus erythematosus
15 Jun 2007 Algeta demonstrates targeted cancer-killing potential of novel alpha particle linked antibodies in leading medical journal Blood
15 Jun 2007 Genmab initiates ofatumumab frontline NHL study
14 Jun 2007 ENBREL Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULAR
13 Jun 2007 Favrille Acquires Anti-CD20 Monoclonal Antibodies from Diversa
12 Jun 2007 Viventia Biotech initiates patient treatment for Phase I trial of VB6-845 anti-cancer antibody
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 451 - 500 of 1062

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Toll-Like Receptor (TLR) Agonists & Antagonists

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics